SEC Form 4 · accession 0001209191-17-003368
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy J. Ackerman
Officer — SVP, Commercial Operations
Period of report
Jan 10, 2017
Accepted (ET)
Jan 11, 2017 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 10, 2017 | M | 7,860 | $7.48 | A | 39,314 | D | |
| Ordinary Shares | Jan 10, 2017 | M | 1,815 | $2.40 | A | 41,129 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.48 | Jan 10, 2017 | M | 7,860 | D | — | Sep 28, 2021 | Ordinary Shares | 7,860 | 0 | D |
| Stock Option (Right to Buy)F1 | $2.40 | Jan 10, 2017 | M | 1,815 | D | — | Jan 1, 2023 | Ordinary Shares | 1,815 | 0 | D |
Explanation of responses
- F1The option is fully vested and exercisable.